Opportunities in China
Currently we are actively helping Chinese clients seek strategic partners. Contact us if your product is falling into these categories and you are interested in exploring potential possibilities in China market.
- Bispecific antibody/ADC drugs. A few recent successful partnership cases are as follows:
- Abpro and China’s NJCTTQ Ink $4 Billion Development Deal.
- Shanghai Miracogen will pay up to €111M ($125M) to develop cancer treatments based on antibody-drug conjugate technology from the Dutch company Synaffix.
- MacroGenics and Zai Lab Announce Exclusive Collaboration and License Agreement to Develop and Commercialize MGD013 and TRIDENT Molecule in Greater China.
- Orthopedics medical devices/consumables. Biocompatible bone cement, arthroscope, and Cross-linked hyaluronan injection for osteoarthritis (Synvisc-One similar products), are highly desired.
|More Opportunities Available
Recognized by IFLR1000 as a leading lawyer for M&A. Has advised on mergers and acquisitions transactions with an aggregate value over US$10 billion.
|Register to Schedule 1-1 Meeting with Other Attendees
- April 30, Online zoom webinar
- June 2, Philadelphia
- 1-to-1 partnering opportunities with potential Chinese investors.
- Exhibition space for your company at China Focus@BIO Philadelphia with a surprise discount.
|Submit Application Now